# EDGAR Filing Document

**Accession Number:** 0001964738
**File Stem:** 0001964738-25-000084
**Filing Date:** 2025-9
**Character Count:** 36029
**Document Hash:** 6ae920442f259540d9a55040bde06af1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001964738-25-000084.hdr.sgml**: 20250908

**ACCESSION NUMBER**: 0001964738-25-000084

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20250908

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250908

**DATE AS OF CHANGE**: 20250908

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Solventum Corp
- **CENTRAL INDEX KEY:** 0001964738
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 922008841
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41968
- **FILM NUMBER:** 251300493

**BUSINESS ADDRESS:**
- **STREET 1:** C/O 3M COMPANY
- **STREET 2:** 3M CENTER, BUILDING 275-6W-02
- **CITY:** ST. PAUL
- **STATE:** MN
- **ZIP:** 55144-1000
- **BUSINESS PHONE:** 651-733-1110

**MAIL ADDRESS:**
- **STREET 1:** C/O 3M COMPANY
- **STREET 2:** 3M CENTER, BUILDING 275-6W-02
- **CITY:** ST. PAUL
- **STATE:** MN
- **ZIP:** 55144-1000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 3M Health Care Co
- **DATE OF NAME CHANGE:** 20230203

?xml version='1.0' encoding='ASCII'? solv-20250908

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **September 8, 2025**

**SOLVENTUM CORPORATION**

(Exact Name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **File No. 001-41968** | **92-2008841** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| **3M Center, Building 275-6W 2510 Conway Avenue East, Maplewood, Minnesota** |  | **55144** |
| (Address of Principal Executive Offices) |  | (Zip Code) |

---

(Registrant's Telephone Number, Including Area Code) **(651) 733-1110**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, Par Value $.01 Per Share | SOLV | New York Stock Exchange |

---

Securities registered pursuant to section 12(g) of the Act: **None**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp; ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the exchange Act.&nbsp;&nbsp;&nbsp;&nbsp; ☐

------

**Item 8.01. Other Events.**

*Results and Upsizing of Note Tender Offers*

On September 8, 2025, Solventum Corporation (the "Company") issued a press release announcing the results as of the early participation date and upsizing of its previously announced cash tender offers to purchase certain of its outstanding debt securities (the "Tender Offers"). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

*Pricing of Note Tender Offers*

On September 8, 2025, the Company issued a press release announcing the pricing terms of the Tender Offers. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated into this Item 8.01 by reference.

The information contained in this Current Report on Form 8-K does not constitute an offer to sell, a solicitation to buy, or an offer to purchase any securities. The Tender Offers are being made only pursuant to the Offer to Purchase dated August 22, 2025, as amended by the Company's press release dated September 8, 2025 announcing the results and upsizing of the Tender Offers. The Tender Offers are being made only in such jurisdictions as is permitted under applicable law.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| Exhibit Number | Description |
| 99.1 | <u>[Press release announcing the results as of the early participation date and upsizing of the Tender Offers, dated September 8, 2025.](tenderofferearlytenderresu.htm)</u> |
| 99.2 | <u>[Press release announcing the pricing terms of the Tender Offers, dated September 8, 2025.](tenderofferpricing-ex992pr.htm)</u> |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| SOLVENTUM CORPORATION | SOLVENTUM CORPORATION |
| By: | /s/ Wayde McMillan |
|  | Wayde McMillan |
|  | Executive Vice President and Chief Financial Officer |

---

Dated: September 8, 2025

## Exhibit 99.1

![image_0.jpg](image_0.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Exhibit 99.1**

**Solventum Announces Early Tender Results and Upsizing of its Note Tender Offers**

ST. PAUL, Minn., Sept. 8, 2025 — Solventum (NYSE: SOLV) today announced the early tender results of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase its outstanding notes of the series listed in the table below (collectively, the "Notes") for an aggregate purchase price of up to an amended $2.0 billion in cash (the "Aggregate Cap"). Solventum has amended the terms of the Tender Offers to (i) increase the Aggregate Cap from $1.75 billion to $2 billion, (ii) increase the previously announced Pool 1 Maximum Amount (as defined below) from $1.25 billion to $1.5 billion and (iii) within the upsized Pool 1 Maximum Amount, increase the previously announced Tender SubCap (as defined below) from $500 million to $650 million. The Tender Offers are being made pursuant to the terms and subject to the conditions set forth in the offer to purchase dated Aug. 22, 2025, as modified by this press release (the "Offer to Purchase").

The Information and Tender Agent (as defined below) for the Tender Offers has advised Solventum that, as of 5:00 p.m., Eastern Time, on Sept. 5, 2025 (such time and date, the "Early Tender Date"), the aggregate principal amount of each series of Notes listed in the table below had been validly tendered and not validly withdrawn in each Tender Offer. Withdrawal rights for the Notes expired at 5:00 p.m., Eastern Time, on Sept. 5, 2025.

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Title of Security** | **CUSIPs** | **Aggregate Principal Amount Outstanding** | **Maturity Date** | **Par Call Date**<sup>1</sup> | **Maximum Amount**<sup>2</sup> | **Acceptance Priority Level**<sup>3</sup> | **Tender SubCap**<sup>4</sup> | **U.S. Treasury Reference Security** | **Bloomberg Reference Page** | **Fixed Spread** | **Aggregate Principal Amount Tendered <br>at Early Tender Date** |
| **Pool 1 Tender Offers** | 5.450% Senior Notes due 2027 | 83444MAN1 83444MAA9 U83448AA5 | $1000000000 | Feb. 25, 2027 | Jan. 25, 2027 | $1.5 billion | 1 | $650 million | 4.125% UST due January 31, 2027 | FIT4 | +20 bps | $937541000<sup>5</sup> |
| **Pool 1 Tender Offers** | 5.400% Senior Notes due 2029 | 83444MAP6 83444MAC5 U83448AB3 | $1500000000 | March 1, 2029 | Feb. 1, 2029 | $1.5 billion | 2 | N/A | 3.875% UST due July 31, 2030 | FIT1 | +30 bps | $1302683000<sup>5</sup> |
| **Pool 1 Tender Offers** | 5.600% Senior Notes due 2034 | 83444MAR2 83444MAG6 U83448AD9 | $1650000000 | March 23, 2034 | Dec. 23, 2033 | $1.5 billion | 3 | N/A | 4.250% UST due August 15, 2035 | FIT1 | +65 bps | N/A<sup>6</sup> |
| **Pool 1 Tender Offers** | 5.450% Senior Notes due 2031 | 83444MAQ4 83444MAE1 U83448AC1 | $1000000000 | March 13, 2031 | Jan. 13, 2031 | $1.5 billion | 4 | N/A | 3.875% UST due July 31, 2030 | FIT1 | +55 bps | N/A<sup>6</sup> |
| **Pool 2 Tender Offers** | 6.000% Senior Notes due 2064 | 83444MAT8 83444MAL5 U83448AF4 | $500000000 | May 15, 2064 | Nov. 15, 2063 | $500 million | 1 | N/A | 4.750% UST due May 15, 2055 | FIT1 | +100 bps | $457552000 |
| **Pool 2 Tender Offers** | 5.900% Senior Notes due 2054 | 83444MAS0 83444MAJ0 U83448AE7 | $1250000000 | April 30, 2054 | Oct. 30, 2053 | $500 million | 2 | N/A | 4.750% UST due May 15, 2055 | FIT1 | +85 bps | $858803000<sup>5</sup> |

---

<sup>1</sup> If the repurchase yield as determined in accordance with the Offer to Purchase is less than the contractual annual rate of interest on a particular series of Notes, then the calculation will assume that the payments of such Notes are through the par call date of such Notes; if the repurchase yield as determined in accordance with the Offer to Purchase is higher than or equal to the contractual annual rate of interest on a particular series of Notes, then the calculation will assume that the payments of such Notes are through the maturity date of the Notes of such series.

<sup>2</sup> The "Pool 1 Maximum Amount" of $1.5 billion represents the maximum aggregate purchase price of Pool 1 Notes (as defined below) that Solventum is offering to purchase in the priorities set forth in the table above. The "Pool 2 Maximum Amount" of $500 million represents the maximum aggregate purchase price of Pool 2 Notes (as defined below) that Solventum is offering to purchase in the priorities set forth in the table above. The Pool 1 Maximum Amount and the Pool 2 Maximum Amount are each referred to as a "Maximum Amount."

<sup>3</sup> Subject to the Aggregate Cap, the Maximum Amounts, the Tender SubCap and proration, if applicable, the aggregate principal amount of each series of Notes that is purchased in the Tender Offer for that series will be determined in accordance with the order of priority set forth in the table (in numerical priority order) (the "Acceptance Priority Level") specified in this column.

<sup>4</sup> The Tender Offer with respect to the 5.450% Senior Notes due 2027 is subject to an aggregate principal amount sublimit of $650 million (the "Tender SubCap").

<sup>5</sup> Solventum expects to accept the 5.450% Senior Notes due 2027, 5.400% Senior Notes due 2029 and 5.900% Senior Notes due 2054 for purchase on a prorated basis.

<sup>6</sup> Solventum does not expect to accept for purchase any of the 5.600% Senior Notes due 2034 or 5.450% Senior Notes due 2031.

Because the series of Notes indicated in the table above next to "Pool 1 Tender Offers" (the "Pool 1 Notes") validly tendered and not validly withdrawn prior to or at the Early Tender Date are expected to have an aggregate purchase price that exceeds the Pool 1 Maximum Amount, Solventum does not expect to accept for purchase all Pool 1 Notes that have been validly tendered and not validly withdrawn prior to or at the Early Tender Date. Because the series of Notes indicated in the table above next to "Pool 2 Tender Offers" (the "Pool 2 Notes") validly

<br> <br> <br>

------

*Solventum 2025 Tender Offer Early Results Press Release&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;* **Page 2 of 3**

tendered and not validly withdrawn prior to or at the Early Tender Date are expected to have an aggregate purchase price that exceeds the Pool 2 Maximum Amount, Solventum does not expect to accept for purchase all Pool 2 Notes that have been validly tendered and not validly withdrawn prior to or at the Early Tender Date. As described further in the Offer to Purchase, the amounts of 5.450% Senior Notes due 2027, 5.400% Senior Notes due 2029 and 5.900% Senior Notes due 2054 that will be purchased will be determined on a prorated basis, subject to the applicable Acceptance Priority Level, and Notes tendered and not accepted for purchase will be promptly credited to the tendering holder's account or otherwise returned to the holder without cost.

Although the Tender Offers are scheduled to expire at 5:00 p.m., Eastern Time, on Sept. 22, 2025, because the Notes validly tendered and not validly withdrawn prior to or at the Early Tender Date are expected to have an aggregate purchase price or aggregate principal amount that exceeds the Aggregate Cap, the Tender SubCap, the Pool 1 Maximum Amount and the Pool 2 Maximum Amount, as applicable, Solventum does not expect to accept for purchase any Notes tendered after the Early Tender Date on a subsequent settlement date.

The "Total Consideration" per $1,000 principal amount of Notes of a given series validly tendered (and not validly withdrawn) and accepted for purchase pursuant to the Tender Offer for that series will be determined in the manner described in the Offer to Purchase by reference to (i) the applicable fixed spread for such series of Notes set forth in the table above (each, a "Fixed Spread") and (ii) the applicable yield for such series of Notes based on the bid-side price of the applicable U.S. Treasury Reference Security set forth in the table above, as displayed on the applicable Bloomberg Reference Page set forth in the table above, at 10:00 a.m., Eastern Time, on Sept. 8, 2025, as such date and time may be extended. The Total Consideration, calculated as described in the preceding sentence, includes the early tender payment of $30 per $1,000 principal amount of Notes of validly tendered prior to or at the Early Tender Date and accepted for purchase. In addition to the applicable Total Consideration, holders of Notes of a given series accepted for purchase pursuant to the Tender Offer for that series will receive accrued and unpaid interest on the Notes accepted for purchase from and including the most recent interest payment date to but excluding the settlement date, which is currently expected to be Sept. 10, 2025.

Solventum will issue a press release specifying the Total Consideration for each series of Notes expected to be accepted for purchase.

Solventum's obligation to accept for purchase, and to pay for, Notes that are validly tendered (and not validly withdrawn) pursuant to the Tender Offers is subject to the satisfaction or waiver by Solventum of certain conditions to the Tender Offers set forth in the Offer to Purchase including, among other things, Solventum having received and repatriated the proceeds from its previously announced sale of its purification and filtration business, excluding the drinking water filtration business, to Thermo Fisher Scientific Inc. pursuant to the Amended and Restated Transaction Agreement dated as of June 25, 2025, as the same may be amended from time to time (the "Financing Condition"). None of the Tender Offers is conditioned upon the completion of any other Tender Offer. In addition, the Tender Offers are not conditioned on any minimum aggregate principal amount of Notes of any series being tendered. As of the date of this press release, the Financing Condition has been satisfied.

J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC are acting as the lead dealer managers in connection with the Tender Offers (collectively, the "Lead Dealer Managers" and, together with the co-dealer managers named in the Offer to Purchase, the "Dealer Managers"). D.F. King & Co., Inc. is acting as the information and tender agent in connection with the Tender Offers (the "Information and Tender Agent"). Requests for assistance relating to the Tender Offers or for additional copies of the Offer to Purchase or other related documents may be directed to J.P. Morgan Securities LLC at (212) 834-3554 (collect) and (866) 834-4666 (toll free), Morgan Stanley & Co. LLC at (212) 761-1057 (collect) and (800) 624-1808 (toll free), Barclays Capital Inc. at (212) 528-7581 (collect) and (800) 438-3242 (toll free) and Goldman Sachs & Co. LLC at (212) 357-1452 (collect) and (800) 828-3182 (toll free), as the Lead Dealer Managers, or to the Information and Tender Agent at (212) 771-1130 (banks and brokers), (877) 478-5045 (toll free) and SOLV@dfking.com. Holders of the Notes may also contact their broker, dealer, commercial bank, trust company or other nominee or intermediary for assistance concerning the Tender Offers. Holders of the Notes are urged to review the Offer to Purchase for the detailed terms of the Tender Offers and the procedures for tendering their Notes.

Neither the Offer to Purchase nor any related document has been filed with the U.S. Securities and Exchange Commission, nor have any such documents been filed with or reviewed by any federal or state securities commission or regulatory authority of any country. No authority has passed upon the accuracy or adequacy of the Offer to Purchase or any related documents, and it is unlawful and may be a criminal offense to make any representation to the contrary.

*This press release does not constitute an offer to purchase, or a solicitation of an offer to sell, or the solicitation of tenders with respect to, the Notes or any other securities. No offer, solicitation, purchase or sale will be made in* 

------

*Solventum 2025 Tender Offer Early Results Press Release&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;* **Page 3 of 3**

*any jurisdiction in which such an offer, solicitation, purchase or sale would be unlawful. The Tender Offers are being made solely pursuant to the Offer to Purchase and only to such persons and in such jurisdictions as is permitted under applicable law. None of Solventum or its affiliates, their respective boards of directors, the Dealer Managers, the Information and Tender Agent or the trustee with respect to any series of Notes makes any recommendation as to whether holders of the Notes should tender, or refrain from tendering, all or any portion of the principal amount of their Notes pursuant to the Tender Offers, and no one has been authorized by any of them to make such a recommendation. Holders of the Notes must make their own decision as to whether to tender any of their Notes and, if so, the principal amount of their Notes to tender pursuant to the Tender Offers.*

**Forward-Looking Statements**

This release contains forward-looking statements, including regarding the timing, terms and completion of the Tender Offers. All statements that are not statements of historical fact are forward-looking statements. Such statements are based upon the current beliefs and expectations of Solventum's management and are subject to risks and uncertainties. Actual results could differ materially from those expressed in or implied by the forward-looking statements contained in this release because of a variety of factors, including, but not limited to, general market conditions which might affect the Tender Offers and other factors identified in the Offer to Purchase. For a discussion of such risks and other factors that might impact forward-looking statements, see "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the U.S. Securities and Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

**<u>About Solventum</u>**

At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best.

**<u>Solventum Investor Contact:</u>**

investors@solventum.com

**<u>Solventum Media Contact:</u>**

news@solventum.com

## Exhibit 99.2

![image_0a.jpg](image_0a.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Exhibit 99.2**

**Solventum Announces Pricing of its Upsized $2 Billion Note Tender Offers**

ST. PAUL, Minn., Sept. 8, 2025—Solventum (NYSE: SOLV) today announced the pricing terms of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase for an aggregate purchase price of up to $2.0 billion in cash (the "Aggregate Cap") specified series of its outstanding notes (collectively, the "Notes"). The Tender Offers are being made pursuant to the terms and subject to the conditions set forth in the offer to purchase dated Aug. 22, 2025, as modified by Solventum's prior press release dated Sept. 8, 2025 increasing the Aggregate Cap, the Pool 1 Maximum Amount (as defined below) and the Tender SubCap (as defined below) (the "Offer to Purchase").

The table below sets forth, among other things, the Total Consideration for each series of Notes that is being accepted for purchase, as calculated at 10:00 a.m., Eastern Time, on Sept. 8, 2025.

---

| | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Title of Security** | **CUSIPs** | **Aggregate Principal Amount Outstanding** | **Maturity Date** | **Par Call Date**<sup>1</sup> | **Acceptance Priority Level**<sup>2</sup> | **U.S. Treasury Reference Security** | **Bloomberg Reference Page** | **Fixed Spread** | **Reference Yield** | **Total Consideration**<sup>3,4</sup> | **Approximate** <br>**Aggregate Principal Amount Expected <br>to be Accepted** | **Approximate Proration Factor** |
| **Pool 1 Tender Offers** | 5.450% Senior Notes due 2027 | 83444MAN1 83444MAA9 U83448AA5 | $1000000000 | Feb. 25, 2027 | Jan. 25, 2027 | 1 | 4.125% UST due January 31, 2027 | FIT4 | +20 bps | 3.620% | $1021.65 | $650000000 | 69.35% |
| **Pool 1 Tender Offers** | 5.400% Senior Notes due 2029 | 83444MAP6 83444MAC5 U83448AB3 | $1500000000 | March 1, 2029 | Feb. 1, 2029 | 2 | 3.875% UST due July 31, 2030 | FIT1 | +30 bps | 3.564% | $1048.41 | $797328000 | 61.24% |
| **Pool 2 Tender Offers** | 6.000% Senior Notes due 2064 | 83444MAT8 83444MAL5 U83448AF4 | $500000000 | May 15, 2064 | Nov. 15, 2063 | 1 | 4.750% UST due May 15, 2055 | FIT1 | +100 bps | 4.723% | $1042.69 | $457552000 | N/A |
| **Pool 2 Tender Offers** | 5.900% Senior Notes due 2054 | 83444MAS0 83444MAJ0 U83448AE7 | $1250000000 | April 30, 2054 | Oct. 30, 2053 | 2 | 4.750% UST due May 15, 2055 | FIT1 | +85 bps | 4.723% | $1046.10 | $21904000 | 2.58% |

---

<sup>1</sup> If the repurchase yield as determined in accordance with the Offer to Purchase is less than the contractual annual rate of interest on a particular series of Notes, then the calculation will assume that the payments of such Notes are through the par call date of such Notes; if the repurchase yield as determined in accordance with the Offer to Purchase is higher than or equal to the contractual annual rate of interest on a particular series of Notes, then the calculation will assume that the payments of such Notes are through the maturity date of the Notes of such series.

<sup>2</sup> The "Pool 1 Maximum Amount" of $1.5 billion represents the maximum aggregate purchase price of the series of Notes indicated in the table above next to "Pool 1 Tender Offers" that Solventum is offering to purchase in the priorities set forth in the table above. The "Pool 2 Maximum Amount" of $500 million represents the maximum aggregate purchase price of the series of Notes indicated in the table above next to "Pool 2 Tender Offers" that Solventum is offering to purchase in the priorities set forth in the table above. The Pool 1 Maximum Amount and the Pool 2 Maximum Amount are each referred to as a "Maximum Amount." The Tender Offer with respect to the 5.450% Senior Notes due 2027 is subject to an aggregate principal amount sublimit of $650 million (the "Tender SubCap"). Subject to the Aggregate Cap, the Maximum Amounts, the Tender SubCap and proration, if applicable, the aggregate principal amount of each series of Notes that is purchased in the Tender Offer for that series has been determined in accordance with the order of priority set forth in the table (in numerical priority order) (the "Acceptance Priority Level") specified in this column.

<sup>3</sup> Includes an early tender payment of $30 per $1,000 principal amount of Notes of each series validly tendered (and not validly withdrawn) prior to or at the Early Tender Date and accepted for purchase pursuant to the applicable Tender Offer.

<sup>4</sup> The Total Consideration is calculated using the applicable Fixed Spread for the Notes of such series. The Total Consideration for each series of Notes validly tendered prior to or at 5:00 p.m., Eastern Time, on Sept. 5, 2025 (the "Early Tender Date") and accepted for purchase is inclusive of the applicable early tender payment. The Total Consideration for each series of Notes does not include the applicable accrued interest, which will be payable in addition to the applicable Total Consideration.

Due to the applicable Maximum Amounts, Solventum will not accept for purchase any of the 5.600% Senior Notes due 2034 or 5.450% Senior Notes due 2031.

Notes tendered and not accepted for purchase will be promptly credited to the tendering holder's account or otherwise returned to the holder without cost.

In addition to the applicable Total Consideration for each series of Notes, holders of Notes accepted for purchase will also receive accrued and unpaid interest on Notes validly tendered and accepted for purchase from and including the applicable most recent interest payment date up to but excluding the settlement date, which is currently expected to be Sept. 10, 2025 (the "Settlement Date").

<br> <br> <br>

------

*Solventum 2025 Tender Offer Pricing Press Release&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;* **Page 2 of 2**

The applicable Total Consideration listed in the table above will be paid per $1,000 principal amount of each series of Notes validly tendered and accepted for purchase pursuant to the applicable Tender Offer on the Settlement Date. Only holders of Notes who validly tendered and did not validly withdraw their Notes prior to or at the Early Tender Date are eligible to receive the applicable Total Consideration for Notes accepted for purchase.

J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC are acting as the lead dealer managers in connection with the Tender Offers (collectively, the "Lead Dealer Managers" and, together with the co-dealer managers named in the Offer to Purchase, the "Dealer Managers"). D.F. King & Co., Inc. is acting as the information and tender agent in connection with the Tender Offers (the "Information and Tender Agent"). Requests for assistance relating to the Tender Offers or for additional copies of the Offer to Purchase or other related documents may be directed to J.P. Morgan Securities LLC at (212) 834-3554 (collect) and (866) 834-4666 (toll free), Morgan Stanley & Co. LLC at (212) 761-1057 (collect) and (800) 624-1808 (toll free), Barclays Capital Inc. at (212) 528-7581 (collect) and (800) 438-3242 (toll free) and Goldman Sachs & Co. LLC at (212) 357-1452 (collect) and (800) 828-3182 (toll free), as the Lead Dealer Managers, or to the Information and Tender Agent at (212) 771-1130 (banks and brokers), (877) 478-5045 (toll free) and SOLV@dfking.com. Holders of the Notes may also contact their broker, dealer, commercial bank, trust company or other nominee or intermediary for assistance concerning the Tender Offers. Holders of the Notes are urged to review the Offer to Purchase for the detailed terms of the Tender Offers and the procedures for tendering their Notes.

Neither the Offer to Purchase nor any related document has been filed with the U.S. Securities and Exchange Commission, nor have any such documents been filed with or reviewed by any federal or state securities commission or regulatory authority of any country. No authority has passed upon the accuracy or adequacy of the Offer to Purchase or any related documents, and it is unlawful and may be a criminal offense to make any representation to the contrary.

*This press release does not constitute an offer to purchase, or a solicitation of an offer to sell, or the solicitation of tenders with respect to, the Notes or any other securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, purchase or sale would be unlawful. The Tender Offers are being made solely pursuant to the Offer to Purchase and only to such persons and in such jurisdictions as is permitted under applicable law. None of Solventum or its affiliates, their respective boards of directors, the Dealer Managers, the Information and Tender Agent or the trustee with respect to any series of Notes makes any recommendation as to whether holders of the Notes should tender, or refrain from tendering, all or any portion of the principal amount of their Notes pursuant to the Tender Offers, and no one has been authorized by any of them to make such a recommendation. Holders of the Notes must make their own decision as to whether to tender any of their Notes and, if so, the principal amount of their Notes to tender pursuant to the Tender Offers.*

**Forward-Looking Statements**

This release contains forward-looking statements, including regarding the timing, terms and completion of the Tender Offers. All statements that are not statements of historical fact are forward-looking statements. Such statements are based upon the current beliefs and expectations of Solventum's management and are subject to risks and uncertainties. Actual results could differ materially from those expressed in or implied by the forward-looking statements contained in this release because of a variety of factors, including, but not limited to, general market conditions which might affect the Tender Offers and other factors identified in the Offer to Purchase. For a discussion of such risks and other factors that might impact forward-looking statements, see "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the U.S. Securities and Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

**<u>About Solventum</u>**

At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best.

**<u>Solventum Investor Contact:</u>**

investors@solventum.com

**<u>Solventum Media Contact:</u>**

news@solventum.com

Solventum Confidential